15 results
10-K
2020 FY
BOLT
Bolt Biotherapeutics Inc
31 Mar 21
Annual report
4:06pm
on the lives of patients, they also have several shortcomings and limitations:
T cell exhaustion: Due to chronic antigen stimulation, activated T … for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union
424B4
BOLT
Bolt Biotherapeutics Inc
5 Feb 21
Prospectus supplement with pricing info
4:44pm
:
T cell exhaustion: Due to chronic antigen stimulation, activated T cells become less effective over time, losing much of their function due … , prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives
S-1/A
5uq10ptv2tw0qb64i
1 Feb 21
IPO registration (amended)
6:24am
S-1
EX-10.18
4td1vjk
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.17
7ntf u4vngdtnqdhn4i3
15 Jan 21
IPO registration
3:58pm
S-1
wl5qkp17xmw9tg twg7
15 Jan 21
IPO registration
3:58pm
DRS/A
lic tb3lu0qen7rd
11 Jan 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.18
aqonr6mzi
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.17
uvl3f8atepkfxw
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
8p9gags6y3ls7
11 Sep 20
Draft registration statement (amended)
12:00am
DRS
dic17pbr79g0 m0ky
10 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next